|
Real-world evidence for U.S. Food and Drug Administration-approved oncology products, 2015 to 2020. |
|
|
Employment - Pfizer; Pfizer (I) |
Stock and Other Ownership Interests - Pfizer; Pfizer (I) |
|
|
No Relationships to Disclose |
|
|
Research Funding - Bayer (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen Scientific Affairs (Inst); Mallinckrodt (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst); Takeda (Inst) |
|
|
Employment - Analysis Group |
Research Funding - AstraZeneca (Inst); Blueprint Medicines (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen (Inst); Kiniksa (Inst); LivaNova (Inst); Mallinckrodt (Inst); Medtronic (Inst); Merck (Inst); Novartis (Inst); Novo Nordisk (Inst); Novo Nordisk (Inst); Pfizer (Inst); Sanofi/Regeneron (Inst); Seagen (Inst); Takeda (Inst); Vertex (Inst); ViiV Healthcare (Inst) |
Expert Testimony - Bayer (Inst) |
|
|
Research Funding - Epizyme; Epizyme; Novartis; Pfizer; Taiho Pharmaceutical |
Travel, Accommodations, Expenses - Novartis |
|
|
Research Funding - Novartis (Inst); Pfizer (Inst) |
|
|
Research Funding - GlaxoSmithKline (Inst); Kiniksa (Inst); Medtronic (Inst); Pfizer (Inst); Takeda (Inst); Taris (Inst) |
|
|
|
Stock and Other Ownership Interests - Pfizer |
Travel, Accommodations, Expenses - Pfizer |